

### **Annex III**

**Amendments to relevant sections of the summaries of product characteristics and package leaflets**

## **A. Summary of Product Characteristics**

### **4.1 Therapeutic indications**

*[the below currently approved indications should be deleted (specific wording of the indication may vary from product to product)]*

- Symptomatic treatment of chronic pathological cognitive and neurosensorial impairment in elderly (excluding Alzheimer's disease and other dementia)
- Ancillary treatment of intermittent claudication in symptomatic peripheral arterial occlusive disease (PAOD Stage II)
- Ancillary treatment of Raynaud's syndrome
- Ancillary treatment of visual acuity decrease and visual field disturbances presumably of vascular origin
- Acute retinopathies of vascular origin
- Prophylaxis of migraine headache

All references to the above mentioned indications should be deleted from the remaining relevant sections of the summaries of product characteristics.

## **B. Package Leaflet**

All references to the above mentioned indications should be deleted from the relevant sections of the package leaflets.